Abstract #3690

First-in-woman study of in vivo breast cancer metabolism using hyperpolarized [1-13C] pyruvate

Kristin L Granlund^1,2, Elizabeth A Morris³, Hebert A Vargas³, Serge K Lyashchenko⁴, Phillip J DeNoble⁴, Virgilio A Sacchini⁵, Ramon A Sosa³, Matthew A Kennedy³, Duane Nicholson³, YanWei W Guo³, Albert P Chen⁶, James Tropp⁷, Hedvig Hricak^2,3, and Kayvan A Keshari^2,3

¹Radiology, Memorial Sloan Kettering, New York, NY, United States, ²Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ³Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁴Radiochemistry & Imaging Probes (RMIP) Core, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁵Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States, ⁶GE Healthcare, Toronto, ON, Canada, ⁷GE Healthcare, Fremont, CA, United States

This is a first-in-woman study of hyperpolarized (HP) pyruvate to study in vivo cancer metabolism. A patient with biopsy-proven breast cancer has been scanned with a 2D dynamic hyperpolarized pyruvate protocol. This study aims to evaluate the feasibility and repeatability of HP breast cancer imaging. HP pyruvate imaging may be useful for evaluating treatment response before and after targeted as well as chemo-therapy or radiation treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here